Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
JNK Clogs Axonal Transport
5 June 2006. Neurons, with their large cell bodies and extensive processes, depend on a delicately balanced intracellular transport machinery to keep in touch with their own outer reaches. Inequalities between kinesin-powered anterograde and dynein-meditated retrograde shipments can result in swollen axons or starved synapses. Three years ago, Scott T. Brady and his colleagues at the University of Illinois at Chicago reported that polyglutamine (polyQ) expanded proteins, including huntingtin, inhibit axonal transport (see ARF related news story). That work, and more since, has led to the suggestion that the neurotoxicity of polyQ expanded proteins results from their ability to cut the axonal supply chain, but just how this occurs was not clear.

Now the Brady lab has provided an answer to that question. In a paper just out online in Nature Neuroscience, they report that the polyQ expanded androgen receptor (the cause of spinal bulbar muscular atrophy) inhibits fast axonal transport by activating the c-jun N-terminal kinase (JNK). JNK then phosphorylates the kinesin heavy chain subunit, inhibiting its binding to microtubules. JNK inhibitors blocked the effects of the polyQ expanded AR on axonal transport in an extruded squid axon preparation, and also reversed inhibition of neurite outgrowth by the pathogenic protein in human cells. The results identify a new pathway by which polyQ expanded proteins can cause neurodegeneration, and suggest that JNK may be a promising target for treatment of spinal and bulbar muscular atrophy (SBMA). On top of that, Brady told Alzforum that his group has a manuscript in preparation showing similar effects with the polyQ expanded Huntington disease protein, huntingtin.

The new work follows up on Gyorgyi Szebenyi’s report that both polyQ-AR and polyQ-huntingtin inhibited axonal transport in an isolated squid axoplasm preparation. First authors Gerardo Morfini and Gustavo Pigino systematically examined the basis for this inhibition. First, they showed that polyQ-AR did not bind directly to kinesin 1, as has been suggested. The pathogenic protein did not affect the membrane association of kinesin 1 in cells, but did reduce the binding of kinesin to microtubules by an indirect mechanism. SH-SY5Y cells expressing polyQ-AR had increased phosphorylation of kinesin 1 heavy chain. To identify the kinase responsible, the researchers turned to the squid axoplasm vesicle transport assay, where they added polyQ-AR along with a variety of kinase inhibitors. Inhibitors of the stress activated protein kinase (SAPK) family, which includes the p38 map kinases and JNK, was able to block the effects of polyQ-AR, while GSK3 inhibitors and the phosphatase inhibitor okadaic acid had no effect. In SH-SY5Y cells, polyQ-AR expression inhibits neurite outgrowth, and this effect was also reversed by the SAPK inhibitor.

To narrow the field down even more, the researchers showed that polyQ-AR expression induced JNK activity, but not p38 map kinase. In the squid axon, they showed that JNK inhibitors, or a JNK interacting protein (JIP) peptide fragment, could block the polyQ-AR inhibition of transport. Finally, they showed that purified JNK could phosphorylate kinesin 1 heavy chain in vitro, and addition of active JNK to the squid axoplasm recapitulated the effects of polyQ-AR.

Is the slowing of axonal transport the primary lesion in SBMA and other polyQ expansion diseases? Brady and colleagues argue that it may very well be, given the unique dependence of neurons on axonal transport. A slight decrease in transport could allow neurons to function normally for some time before eventually succumbing, they suggest, and account for the delayed onset of many neurodegenerative disorders. Also, a selective vulnerability of neurons would explain why only certain populations die while all cells in the body express the mutated protein.

The idea that dysregulation of protein phosphorylation can lead to axonal transport defects and ultimately neurodegeneration echoes Brady’s previous observations in an Alzheimer disease model. There, a presenilin 1 mutation inhibited axonal transport via activation of glycogen synthase kinase. In mice carrying the M146V FAD mutant, increased activation of GSK3β kinase resulted in phosphorylation of kinesin light chain and lowered its binding to vesicle cargoes. The mice showed signs of compromised transport in the form of lower levels of synaptic vesicles and fewer mitochondria in nerve endings (Pigino et al., 2003). Of course, in AD there is also tau, which comes with its own set of troubles for kinesin-mediated transport and microtubules.—Pat McCaffrey.

Reference:
Morfini G, Pigino G, Szebenyi G, You Y, Pollema S, Brady ST. JNK mediates pathogenic effects of polyglutamine-expanded androgen receptor on fast axonal transport. Nat Neurosci. 2006 Jul;9(7):907-16. Epub 2006 Jun 4. Abstract

 
  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad